73 research outputs found

    Allergic rhinitis

    Get PDF
    Allergic rhinitis is a common disorder that is strongly linked to asthma and conjunctivitis. It is usually a long-standing condition that often goes undetected in the primary-care setting. The classic symptoms of the disorder are nasal congestion, nasal itch, rhinorrhea and sneezing. A thorough history, physical examination and allergen skin testing are important for establishing the diagnosis of allergic rhinitis. Second-generation oral antihistamines and intranasal corticosteroids are the mainstay of treatment. Allergen immunotherapy is an effective immune-modulating treatment that should be recommended if pharmacologic therapy for allergic rhinitis is not effective or is not tolerated. This article provides an overview of the pathophysiology, diagnosis, and appropriate management of this disorder

    Dlgap1 knockout mice exhibit alterations of the postsynaptic density and selective reductions in sociability

    Get PDF
    Abstract The scaffold protein DLGAP1 is localized at the post-synaptic density (PSD) of glutamatergic neurons and is a component of supramolecular protein complexes organized by PSD95. Gain-of-function variants of DLGAP1 have been associated with obsessive-compulsive disorder (OCD), while haploinsufficient variants have been linked to autism spectrum disorder (ASD) and schizophrenia in human genetic studies. We tested male and female Dlgap1 wild type (WT), heterozygous (HT), and knockout (KO) mice in a battery of behavioral tests: open field, dig, splash, prepulse inhibition, forced swim, nest building, social approach, and sucrose preference. We also used biochemical approaches to examine the role of DLGAP1 in the organization of PSD protein complexes. Dlgap1 KO mice were most notable for disruption of protein interactions in the PSD, and deficits in sociability. Other behavioral measures were largely unaffected. Our data suggest that Dlgap1 knockout leads to PSD disruption and reduced sociability, consistent with reports of DLGAP1 haploinsufficient variants in schizophrenia and ASD

    Mechanisms of T cell organotropism

    Get PDF
    F.M.M.-B. is supported by the British Heart Foundation, the Medical Research Council of the UK and the Gates Foundation

    Root-emitted volatile organic compounds: can they mediate belowground plant-plant interactions?

    Full text link
    peer reviewedBackground Aboveground, plants release volatile organic compounds (VOCs) that act as chemical signals between neighbouring plants. It is now well documented that VOCs emitted by the roots in the plant rhizosphere also play important ecological roles in the soil ecosystem, notably in plant defence because they are involved in interactions between plants, phytophagous pests and organisms of the third trophic level. The roles played by root-emitted VOCs in between- and within-plant signalling, however, are still poorly documented in the scientific literature. Scope Given that (1) plants release volatile cues mediating plant-plant interactions aboveground, (2) roots can detect the chemical signals originating from their neighbours, and (3) roots release VOCs involved in biotic interactions belowground, the aim of this paper is to discuss the roles of VOCs in between- and within-plant signalling belowground. We also highlight the technical challenges associated with the analysis of root-emitted VOCs and the design of experiments targeting volatile-mediated root-root interactions. Conclusions We conclude that root-root interactions mediated by volatile cues deserve more research attention and that both the analytical tools and methods developed to study the ecological roles played by VOCs in interplant signalling aboveground can be adapted to focus on the roles played by root-emitted VOCs in between- and within-plant signalling

    A taxonomic bibliography of the South American snakes of the Crotalus durissus complex (Serpentes, Viperidae)

    Full text link

    Análise das demandas judiciais para o fornecimento de medicamentos pela Secretaria de Estado da Saúde de Santa Catarina nos anos de 2003 e 2004 Situation of lawsuits concerning the access to medical products by the Health Department of Santa Catarina State, Brazil, during the years 2003 and 2004

    No full text
    Neste trabalho, é analisada a situação dos processos judiciais contra a Secretaria de Estado de Saúde de Santa Catarina determinando fornecimento de medicamentos em 2003 e 2004. As variáveis consideradas foram: patologia declarada, medicamento solicitado, origem da prescrição, possíveis alternativas terapêuticas na Relação Estadual de Medicamentos (Resme), registro dos medicamentos na Agência Nacional de Vigilância Sanitária (Anvisa) e custos totais. Foram analisados 622 processos, com gasto de R11.333.750,00.Osservic\cosprivadosdesauˊdeoriginaram56 11.333.750,00. Os serviços privados de saúde originaram 56% das prescrições. Hepatite C e artrite reumatoide foram as doenças mais referidas. Em 40% dos casos, os produtos faziam parte da Resme. Dos produtos solicitados, 6,2% tiveram a sua comercialização iniciada no Brasil a partir do ano 2000, destacando-se Interferon Pequilado e Infliximabe, responsáveis por 46% do total dos gastos. Alguns processos envolviam medicamentos que não possuíam registro na Anvisa, e houve casos em que a indicação de uso do medicamento não estava aprovada no país. Os resultados indicam que a reavaliação dos elencos de medicamentos padronizados e a melhoria no acesso aos tratamentos, aliadas à melhor divulgação dos programas de distribuição de medicamentos, são medidas que potencialmente poderão reduzir o número de processos judiciais.<br>This study describes the situation of lawsuits concerning the access to medical products by the Health Department of Santa Catarina State (SES/SC), Brazil, during the years of 2003 and 2004. The variables considered were: declared illnesses, medicines demanded, prescription origin, possible alternatives therapeutics in the Santa Catarina State Register of Essential Medicines (Resme), the medicines registration at the National Health Surveillance Agency (Anvisa) and total expenditure. 622 lawsuits were filed. Total expenditure was R 11,333,750,00 (Brazilian Reais). Private health care was the source of 56% of the prescriptions. Hepatitis C and rheumatoid arthritis were the most commonly diseases involved. About 40% of requested drugs were on the Resme. 6.2% of required drugs were approved in Brazil after 2000. PEG-Interferon and Infliximab were responsible for 46% of total expenditure. There were still some cases of drugs or indications not registered at Anvisa. These results indicate the need to reassess the list of medicines regularly provided by the SES/SC, and also to improve accessibility to (and information concerning) Programs of medicines distribution. These measures may potentially reduce the number of lawsuits filed against the State
    corecore